Biotek-snakken — Maj 2022
-
Biotech Stocks Facing FDA Decision In June 2022
https://www.proinvestor.com/investornyt/830415/biotech-stocks-facing-fda-decision-in-june-2022 -
Here's What AstraZeneca's Recent FDA News Means for Shareholders
https://www.proinvestor.com/investornyt/830734/heres-what-astrazenecas-recent-fda-news-means-for-shareholders -
Købsmulighed? XBRANE BIOPHARMA: PARETO SPÅR XLUCANE-FÖRSENING PÅ 2-4 MÅNADER
9:15
STOCKHOLM (Nyhetsbyrån Direkt) Biosimilarutvecklaren Xbrane Biopharma väntas få en försening på 2-4 månader enligt Pareto Securities.Det framgår av en analyskommentar på måndagen.
Xbrane väntas enligt Pareto få en temporärt negativ kursreaktion på aktien som enligt analyshusets bedömning är kraftigt undervärderad.
Kursen i Xbrane har mer än halverats sedan utläsningen av bolagets fas 3-resultat påpekar Pareto.
-
Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022 – Alligator Bioscience
ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody ATOR-1017 was safe and well tole ...
(alligatorbioscience.se)
-
Fin præsentation om Saniona / ingen tvivl om aktien er alt for lavt prissat: https://www.youtube.com/watch?v=-EkN5W5mE2M
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind